Read by QxMD icon Read

Serotypes pneumococcal

Daniel M Weinberger, Joshua L Warren, Tine Dalby, Eugene D Shapiro, Palle Valentiner-Branth, Hans-Christian Slotved, Zitta Barrella Harboe
Background: Pneumococcal conjugate vaccines (PCVs) have had a well-documented impact on the incidence of invasive pneumococcal disease (IPD). However, declines in IPD due to vaccine-targeted serotypes have been partially offset by increases in IPD due to non-vaccine serotypes (NVT). The goal of this study was to quantify serotype-specific changes in the incidence of IPD that occurred in different age groups, with or without certain co-morbidities, following the introduction of PCV7 and PCV13 in the childhood vaccination program in Denmark...
October 13, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Nirma Khatri Vadlamudi, Anna Chen, Fawziah Marra
BACKGROUND: A notable reduction of pneumococcal disease burden among adults was observed after introduction of 7 valent- pneumococcal conjugate vaccine in childhood immunization programs. In 2010, 13 valent-pneumococcal conjugate vaccine (PCV13) replaced PCV7 in many jurisdictions; a comparative assessment of PCV13's impact has not yet been performed. OBJECTIVE: To summarize available data and assess the change in the incidence of invasive pneumococcal disease (IPD) in adults after the introduction of PCV13 in childhood immunization programs...
October 12, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
S Shahzad Mustafa, Deep Shah, Jonathan Bress, Saad Jamshed
Infections are a major cause of morbidity and mortality in individuals with multiple myeloma (MM). These individuals exhibit humoral dysfunction and show a suboptimal response to pneumococcal polysaccharide vaccine (PPV23). Since pneumococcal conjugate vaccine (PCV13) elicits a T cell dependent response, it is recommended in patients with multiple myeloma. This study compares the initial response to PCV13 and durability of the response at 6 months in patients with multiple myeloma versus normal controls. Seven patients with multiple myeloma and 18 control patients were enrolled in the study...
October 10, 2018: Human Vaccines & Immunotherapeutics
Allison R Thompson, Nicola P Klein, H Jackson Downey, Scott Patterson, Vani Sundaraiyer, Wendy Watson, Keri Clarke, Kathrin U Jansen, Shite Sebastian, William C Gruber, Daniel A Scott, Beate Schmoele-Thoma
Immune responses to 13-valent pneumococcal conjugate vaccine (PCV13) and quadrivalent inactivated influenza vaccine (QIV) in older adults may vary with coadministration and previous pneumococcal polysaccharide vaccination. This study assessed safety and noninferiority of immune responses to coadministered PCV13 and QIV compared with each vaccine given alone. Adults ≥50 years old preimmunized with ≥1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) ≥1 year before enrollment were randomized 1:1 to receive PCV13+QIV then placebo 1 month later or placebo+QIV then PCV13 1 month later...
October 10, 2018: Human Vaccines & Immunotherapeutics
Jennifer C Moïsi, Seydou Yaro, Sita S Kroman, Clarisse Gouem, Dramane Bayane, Seydou Ganama, Bertrand Meda, Boubacar Nacro, Berthe-Marie Njanpop-Lafourcade, Soumeya Ouangraoua, Issaka Ouedraogo, Souleymane Sakande, Francois Sawadogo, Sylvie Zida, Jean-Bosco Ouedraogo, Bradford D Gessner
Background: Many African countries have introduced pneumococcal conjugate vaccine (PCV) into their routine immunization program to reduce the burden of morbidity and death that results from Streptococcus pneumoniae infection, yet immunogenicity and reactogenicity data from the region are limited for the 2 available PCV products. Methods: We conducted a randomized trial of 13-valent PCV (PCV13) in Bobo-Dioulasso, Burkina Faso. Infants received 3 doses of PCV at 6, 10, and 14 weeks of age or at 6 weeks, 14 weeks, and 9 months of age; toddlers received 2 doses 2 months apart or 1 dose beginning at 12 to 15 months of age; and children received 1 dose between 2 and 4 years of age...
October 8, 2018: Journal of the Pediatric Infectious Diseases Society
B Midouni, E Mehiri, A Ghariani, H Draoui, L Essalah, I Bouzouita, D Raoult, L Slim-Saidi, P E Fournier
OBJECTIVE: The objective of this study was to explore the genetic diversity of Streptococcus pneumoniae by using antibiotic susceptibility testing, serotyping and multilocus sequence typing (MLST) in a Tunisian pneumology hospital. MATERIALS AND METHODS: We investigated 141 strains of S.pneumoniae isolated between 2009 and 2016 in the Microbiology Laboratory at Pneumology Hospital A. Mami, Tunisia. Antimicrobial susceptibility was tested using the disk diffusion method...
October 5, 2018: International Journal of Antimicrobial Agents
A Kent, A Makwana, C L Sheppard, S Collins, N K Fry, P T Heath, M Ramsay, S N Ladhani
Background: Invasive pneumococcal disease (IPD) has declined significantly since the introduction of pneumococcal conjugate vaccines (PCV). It is not known whether certain infant populations remain at higher risk of IPD in countries with established PCV13 programmes. We aimed to describe the epidemiology, clinical characteristics, serotype distribution and outcomes of IPD in infants, and to estimate the relative risk of PCV13-type, non-PCV13 type and overall IPD in premature infants compared to term infants during a four-year period after the PCV13 programme was established...
October 3, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Ángel Vila Córcoles, Cristina Dacosta Moreira, Cinta de Diego Cabanes, Olga Ochoa Gondar, Marta Raga Gutiérrez, Frederic Gómez Bertomeu, Xavier Raga Luria, Enric Figuerola Massana
OBJECTIVE: Nowadays, after licensure of the second generation new pneumococcal conjugate vaccines (PCV10/PCV13). The epidemiology of the pneumococcal disease must be re-evaluated. The present study described incidence, lethality and serotype distribution of invasive pneumococcal disease (IPD) in the general population of Tarragona's region (Spain) after licensure of these vaccines. METHODS: Retrospective study that included all cases of IPD (pneumococcus isolated in sterile sites) diagnosed among all-age individuals in the Spanish region of Tarragona (Tarragonés, Alt Camp and Baix Penedés counties) from 01/01/2012 to 31/12/2015...
October 2, 2018: Revista Española de Salud Pública
Evida A Dennis, Mamie T Coats, Sarah Griffin, Bing Pang, David E Briles, Marilyn J Crain, W Edward Swords
Mucoid bacteria, predominately Pseudomonas aeruginosa, are commonly associated with decline in pulmonary function in children with cystic fibrosis (CF), and are thought to persist at least in part due to a greater propensity toward forming biofilms. We isolated a higher frequency of mucoid Streptococcus pneumoniae (Sp) expressing high levels of capsular polysaccharides from sputa from children with CF, compared to those without CF. We compared biofilm formation and maturation by mucoid and non-mucoid isolates of Sp collected from children with and without CF...
September 28, 2018: Pathogens and Disease
Pak-Leung Ho, Pierra Ying-Tung Law, Susan S Chiu
This study used several datasets of reported and serotyped invasive pneumococcal disease (IPD) cases to estimate vaccine and non-vaccine type incidence in Hong Kong children. Incidence was analyzed by four time periods to indicate pre-PCV (period 1, 1995-2004), private market only (period 2, 2006-2009), and following early (period 3, 2010-2014, mixed use of 7-, 10- and 13-valent vaccines) and more than five years (period 4, 2015-2017, 13-valent vaccine only) of routine implementation (since September 2009)...
September 27, 2018: Human Vaccines & Immunotherapeutics
Sigríður J Quirk, Gunnsteinn Haraldsson, Helga Erlendsdóttir, Martha Á Hjálmarsdóttir, Andries J van Tonder, Birgir Hrafnkelsson, Samúel Sigurðsson, Stephen D Bentley, Ásgeir Haraldsson, Angela B Brueggemann, Karl G Kristinsson
Vaccination with pneumococcal conjugate vaccines (PCVs) disrupts the pneumococcal population. Our aim was to determine the impact of the 10-valent PCV on the serotypes, genetic lineages and antimicrobial susceptibility of pneumococci isolated from children in Iceland. Pneumococci were collected between 2009-2017 from the nasopharynx of healthy children attending 15 day-care centres and from the middle ear (ME) of children with acute otitis media from the greater Reykjavik capital area. Isolates were serotyped and tested for antimicrobial susceptibility...
September 26, 2018: Journal of Clinical Microbiology
Chen-Fang Hsu, Chen-Hao Hsiao, Shun-Fu Tseng, Jian-Ru Chen, Yu-Jou Liao, Sy-Jou Chen, Chin-Sheng Lin, Huey-Kang Sytwu, Yi-Ping Chuang
BACKGROUND: Streptococcus pneumoniae is a respiratory pathogen causing severe lung infection that may lead to complications such as bacteremia. Current polysaccharide vaccines have limited serotype coverage and therefore cannot provide maximal and long-term protection. Global efforts are being made to develop a conserved protein vaccine candidate. PrtA, a pneumococcal surface protein, was identified by screening a pneumococcal genomic expression library using convalescent patient serum...
September 25, 2018: Respiratory Research
Izabela Korona-Glowniak, Piotr Zychowski, Radoslaw Siwiec, Elżbieta Mazur, Grażyna Niedzielska, Anna Malm
BACKGROUND: Despite advances in the development of pneumococcal conjugate vaccines, acute otitis media (AOM) is a common childhood infection, caused mainly by Streptococcus pneumoniae. It has been suggested that persistence of pneumococcal nasopharyngeal carriage is a risk factor for subsequent recurrent infections. METHODS: In this study we evaluate the relationship between 55 pneumococcal strains obtained from nasopharynx/oropharynx (NP/OP) and middle ear fluid (MEF) of 62 children, aged between 1 and 16 years, during AOM (including recurrent/treatment failure AOM, and post-treatment visits), based on their phenotypic and genotypic characteristics performed by analyses of serotype, antibiotic susceptibility patterns and multilocus sequence typing...
September 25, 2018: BMC Infectious Diseases
David Greenberg, Patricia A Hoover, Timo Vesikari, Christopher Peltier, David C Hurley, Richard D McFetridge, Michael Dallas, Jonathan Hartzel, Rocio D Marchese, Beth-Ann G Coller, Jon E Stek, Chitrananda Abeygunawardana, Michael A Winters, John E MacNair, Narahari S Pujar, Luwy Musey
BACKGROUND: Pediatric use of pneumococcal conjugate vaccines (PCV) has been associated with significant decrease in disease burden. However, disease caused by non-vaccine serotypes has increased. Safety and immunogenicity of 15-valent PCV (PCV15) containing serotypes included in 13-valent PCV (PCV13) plus serotypes 22F and 33F were evaluated in infants (NCT01215188). METHODS: Infants received adjuvanted PCV15, nonadjuvanted PCV15, or PCV13 at 2, 4, 6, and 12-15 months of age...
September 20, 2018: Vaccine
Patricia Letrado, Bruno Corsini, Roberto Díez-Martínez, Noemí Bustamante, José E Yuste, Pedro García
AIM: To test the synergistic effect of Cpl-711 endolysin and antibiotics for antipneumococcal activity. MATERIALS & METHODS: A combination of Cpl-711 and different antibiotics (amoxicillin, cefotaxime, levofloxacin and vancomycin) was tested in a checkerboard assay against several multidrug-resistant Streptococcus pneumoniae strains. Mouse and zebrafish models of pneumococcal sepsis were used to confirm the in vitro data. RESULTS: The activity of Cpl-711 combined with amoxicillin or cefotaxime was synergistic in the bactericidal effect against a serotype 23F multiresistant clinical isolate of S...
September 2018: Future Microbiology
Sophie Edouard, Jaffar A Al-Tawfiq, Ziad A Memish, Saber Yezli, Philippe Gautret
BACKGROUND: The Islamic Hajj pilgrimage is the largest annual mass gathering in the world. The overcrowding of people promotes the acquisition, spread and transmission of respiratory pathogens, including Streptococcus pneumoniae. METHODS: We conducted a methodological review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The objective was to summarize the available data regarding the prevalence of pneumococcal carriage among Hajj pilgrims and about carriage acquisition and circulation of S...
September 17, 2018: Vaccine
Jingcai Lu, Jieshi Guo, Dandan Wang, Jinfei Yu, Tiejun Gu, Chunlai Jiang, Wei Kong, Yongge Wu
Streptococcus pneumoniae is an infectious pathogen mainly infecting host bodies through the respiratory system. An effective pneumococcal vaccine would be targeted to the mucosa and provide not only protection against invasive infection but also against colonization in the respiratory system. In the present work, we applied bacterium-like particles (BLPs) as an adjuvant for the development of a PspA mucosal vaccine, in which the PspA protein was displayed on the surface of BLPs. Intranasal immunization with the PspA-BLP pneumococcal vaccine, comprised of PspA2 from pneumococcal family 1 and PspA4 from pneumococcal family 2, not only induced a high level of serum IgG antibodies but also a high level of mucosal SIgA antibodies...
September 20, 2018: Human Vaccines & Immunotherapeutics
Ashley Makwana, Shamez N Ladhani, Georgia Kapatai, Ella Campion, Norman K Fry, Carmen Sheppard
We observed a sudden and rapid increase in rare invasive pneumococcal disease serotype 7C, from an annual average of 3 cases during 2000-01 through 2015-16 to 29 cases in 2016-17. The increase was caused almost entirely by clonal expansion of sequence type 177, previously associated with vaccine serotype 19F.
October 2018: Emerging Infectious Diseases
Anukul T Shenoy, Sarah M Beno, Terry Brissac, Jeremiah W Bell, Lea Novak, Carlos J Orihuela
Streptococcus pneumoniae is an opportunistic Gram-positive pathogen that can cause invasive disease. Recent studies have shown that S. pneumoniae is able to invade the myocardium and kill cardiomyocytes, with one-in-five adults hospitalized for pneumococcal pneumonia having a pneumonia-associated adverse cardiac event. Furthermore, clinical reports have shown up to a 10-year increased risk of adverse cardiac events in patients formerly hospitalized for pneumococcal bacteremia. In this study, we investigated the ability of nine S...
2018: PloS One
Betuel Sigaúque, Benild Moiane, Sergio Massora, Fabiana Pimenta, Jennifer R Verani, Helio Mucavele, Alberto Chaúque, Llorenç Quintó, Rita T Dos Santos, Maria da Gloria Carvalho, Cynthia G Whitney, Fernanda C Lessa
BACKGROUND: Pneumococcal carriage is a precursor of invasive pneumococcal disease. Mozambique introduced 10-valent pneumococcal conjugate vaccine (PCV10) in April 2013, using a 3-dose schedule without a booster. We evaluated PCV10 impact on pneumococcal carriage and colonization density by HIV status. METHODS: We conducted 2 cross-sectional surveys (pre and post PCV10 introduction) among children 6 weeks to 59 months old. Participants included HIV-infected children presenting for routine care at outpatient clinics and a random sample of HIV-uninfected children from the community...
October 2018: Pediatric Infectious Disease Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"